NIH PAR · NHLBI · UG3, UH3
PAR-27-012: Clinical Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3 Clinical Trial Required)
Reviewed by Dr. Meng ZhaoLast reviewed October 16, 2026Data refreshed October 16, 2026Editorial standards
This Notice of Funding Opportunity (NOFO) supports applications to develop and conduct a Clinical Coordinating Center (CCC) for investigator-initiated multi-site clinical trials including efficacy, comparative effectiveness, pragmatic and/or dissemination and implementation science clinical trials. Trials using innovative designs such as platform trials, adaptive, and Bayesian designs are encouraged. These trials may include ones that test different therapeutic, behavioral, dissemination and implementation science clinical trials and/or prevention strategies.Trials for which this NOFO applies must be relevant to the research mission of the NHLBI and meet the NIH definition of a clinical…
- NOFO number
- PAR-27-012
- Type
- PAR
- Activity code
- UG3UH3
- Primary institute
- NHLBI · National Heart, Lung, and Blood Institute
- Clinical trials
- Required
- Posted
- Mar 18, 2026
- Opens
- May 2, 2026
- Expires
- Nov 3, 2028
PAR-27-012 due dates
6 application due dates remain before the NOFO expires. Dates marked * are NIH standard due dates. Check the related notices below for changes NIH made after posting.
| New | Renewal / Resubmission / Revision (as allowed) | AIDS - New/Renewal/Resubmission/Revision, as allowed | Scientific Merit Review | Advisory Council Review | Earliest Start Date |
|---|---|---|---|---|---|
| June 02, 2026 | July 02, 2026 | Not Applicable | November 2026 | January 2027 | April 2027 |
| October 02, 2026 | November 02, 2026 | Not Applicable | March 2027 | May 2027 | July 2027 |
| February 01, 2027 | March 01, 2027 | Not Applicable | July 2027 | October 2027 | December 2027 |
| June 02, 2027 | July 02, 2027 | Not Applicable | November 2027 | January 2028 | April 2028 |
| October 01, 2027 | November 01, 2027 | Not Applicable | March 2028 | May 2028 | July 2028 |
| February 01, 2028 | March 01, 2028 | Not Applicable | July 2028 | October 2028 | December 2028 |
| June 01, 2028 | June 30, 2028 | Not Applicable | November 2028 | January 2029 | April 2029 |
| October 02, 2028 | November 02, 2028 | Not Applicable | March 2029 | May 2029 | July 2029 |
What its predecessor PAR-25-029 funded
PAR-27-012 reissues PAR-25-029. Until awards appear under the new number, its funding history is the best guide to who wins under this program: 6 projects and $8.4M in FY2022–FY2026.
Projects funded
6
Distinct projects, FY2022–FY2026
New awards
6
Type 1 (new project) award records
NIH funding
$8.4M
Award dollars under PAR-25-029, FY2022–FY2026
Funding by fiscal year
| Fiscal year | Award records | New awards | Funding |
|---|---|---|---|
| FY2022 | 0 | 0 | $0 |
| FY2023 | 0 | 0 | $0 |
| FY2024 | 0 | 0 | $0 |
| FY2025 | 0 | 0 | $0 |
| FY2026 | 19 | 6 | $8.4M |
Institutions with the most funding
- National Jewish Health$3.1M · 2 projects
- University of Alabama at Birmingham$2.2M · 1 project
- Icahn School of Medicine at Mount Sinai$1.8M · 2 projects
- Ihc Health Services, Inc.$1.3M · 1 project
Funding institutes
- NHLBI$8.4M · 19
Activity codes funded
- UG319 records
Most recent new awards
- 1/2 Precision Tapering of Biologic Therapy in Asthma: Identifying Predictors of Successful Dupilumab Interval Extension (opens NIH RePORTER)
National Jewish Health · 1UG3HL188699-01 · NHLBI · Notice Sep 10, 2026
$2.1MUG3
- 1/2 GLobal trial Of Bromocriptine for PeriPartum CardioMyopathy (GLOBal PPCM) (opens NIH RePORTER)
University of Alabama at Birmingham · 1UG3HL177574-01A1 · NHLBI · Notice Sep 9, 2026
$1.8MUG3
- 1/2 Efficacy and Safety of Obinutuzumab in Connective Tissue Disease-Related Interstitial Lung Disease (opens NIH RePORTER)
National Jewish Health · 1UG3HL183035-01A1 · NHLBI · Notice Sep 8, 2026
$1.0MUG3
- 1/2 Clinical Trial of a MEK Inhibitor for RASopathy-Associated Severe Infantile Hypertrophic Cardiomyopathy (opens NIH RePORTER)
Icahn School of Medicine at Mount Sinai · 1UG3HL185610-01 · NHLBI · Notice Sep 8, 2026
$947KUG3
- 2/2- Antiplatelet Therapy in Spontaneous Coronary Artery Dissection (APT-SCAD) (opens NIH RePORTER)
Icahn School of Medicine at Mount Sinai · 1UG3HL181193-01A1 · NHLBI · Notice Sep 7, 2026
$804KUG3
- (1/2) Catheter Ablation Versus Antiarrhythmic and Heart Failure Drug Therapy in Preserved Ejection Fraction Heart Failure (CABANA-HF) (opens NIH RePORTER)
Ihc Health Services, Inc. · 1UG3HL182948-01 · NHLBI · Notice Jul 9, 2026
$1.3MUG3
FY2026 closed on September 30, 2026, but NIH keeps posting that year's awards to RePORTER for several weeks. FY2026 figures reflect records available on October 16, 2026 and may rise slightly at the next refresh.
Participating institutes
2 NIH institutes and offices take applications under PAR-27-012. Contact the program officer at the institute that fits your research before applying.
- NHLBI · National Heart, Lung, and Blood Institute
- none
Related notices
NIH lists no related notices for PAR-27-012 yet.
Award terms
- Application types allowed
- New Resubmission Revision The OER Glossary and the How to Apply Application Guide provide details on these application types. Only those application types listed here are allowed for this NOFO.
- Award budget
- Application budgets are not limited but need to reflect the actual needs of the proposed project.
- Project period
- The scope of the proposed project should determine the requested project award period.The project period for the UG3 phase will be up to 1 year.The project period for the UH3 phase is expected to be 4 years. With strong justification, up to 6 years for the UH3 may be requested. NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards…
- Funds available and number of awards
- The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.
Summarized from the NOFO text; the full NOFO governs eligibility, budget, and review.
Related NOFOs
- Reissue of PAR-25-029.
- Companion NOFOs: PAR-27-013.
Other open NOFOs for UG3, UH3
- RFA-NS-27-007HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)NINDS · next due Oct 21, 2026
- PAR-27-015Community-Based Participatory Research to Advance Data and Practice Transformation (ADAPT) for Optimizing Oral Health for All (UG3/UH3 Clinical Trial Optional)NIDCR · next due Oct 16, 2026
- RFA-RM-27-012PRIMED-AI: Data-to-Model Academic-Industrial Partnerships (D2M-AIP) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (UG3/UH3 Clinical Trial Optional)RMOD · next due Oct 19, 2026
- RFA-RM-27-013Model-to-Clinic (M2C) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (UG3/UH3, Clinical Trial Optional)RMOD · next due Oct 19, 2026
- PAR-25-296Limited Competition: Clinical and Translational Science Award (CTSA) Program: Collaborative and Innovative Acceleration Award (UG3/UH3 Clinical Trial Optional)NCATS · next due Oct 19, 2026
- PAR-25-226Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)NIA · next due Oct 19, 2026
About this page
GotGrant gathers the NOFO, its participation and change notices, and its NOSIs from the NIH Guide for Grants and Contracts, and counts funded projects from NIH RePORTER by the opportunity number each award was made under. Data refreshed October 16, 2026; the NIH Guide is the authoritative source. See our data methodology.